3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
5
Breast Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasms
3
Melanoma
3
Leukemia, Myeloid, Acute
3
Leukemia
3
Carcinoma, Non-Small-Cell Lung
3
Myelodysplastic Syndromes
2
Lymphoma, Mantle-Cell
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hematologic Neoplasms
2
Craniopharyngioma
2
COVID-19
2
Burkitt Lymphoma
2
Arthritis, Rheumatoid
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Unresectable Pancreatic Carcinoma
1
Triple Negative Breast Neoplasms
1
Stroke
1
Sarcoma
1
Respiratory Tract Infections
1
Recurrence
1
Pulmonary Disease, Chronic Obstructive
1
Prostatic Neoplasms
1
Pleural Effusion, Malignant
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Interventions
Rituximab
7
Pyridostigmine Bromide
5
Prednisone
5
efgartigimod alfa
4
Hizentra
4
telitacicept
3
Immunoglobulins, Intravenous
3
Cyclophosphamide
3
Azathioprine
3
thymoglobulin
2
fludarabine
2
Thymectomy
2
Steroids
2
Mycophenolic Acid
2
Data Collection
2
Blood Specimen Collection
2
zilucoplan
1
tofacitinib
1
tocilizumab
1
talquetamab
1
sargramostim
1
rozanolixizumab
1
prednylidene
1
gamma-Globulins
1
deltacortene
1
carmustine, poliferprosan 20 drug combination
1
bu-zhong-yi-qi-tang
1
apraclonidine
1
Walk Test
1
Therapeutics
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Myasthenia Gravis
×
tocilizumab
×
Clear all
NCT05716035
2024-01-22
tMG-E
Tang-Du Hospital
Phase 2/3
Unknown
64 enrolled